South Korea Multiomics Market (2026-2031)
The South Korea Multiomics Market was valued at $85.4 Million in 2026 and projected to reach to $155.5 Million by 2031, representing a compound annual growth rate of 12.7%. South Korea's multiomics market is experiencing accelerated growth driven by increasing healthcare expenditure, rising prevalence of chronic diseases, and strong government support for precision medicine initiatives.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea Multiomics Market Trends and Insights
- This represents a compound annual growth rate of 12.7%, outpacing global averages and reflecting South Korea's advanced healthcare infrastructure and strong investment in precision medicine technologies.
- South Korea's robust biotechnology ecosystem, coupled with government support for genomic research initiatives, is driving accelerated adoption of multiomics solutions across clinical diagnostics and pharmaceutical development. The expansion of South Korea's multiomics market is underpinned by increasing demand for integrated genomic, proteomic, and metabolomic data in personalized medicine applications.
- South Korea's healthcare providers and research institutions are increasingly leveraging multiomics platforms to enhance disease understanding and treatment efficacy.
- Between 2026 and 2031, South Korea is expected to see significant investments in multiomics infrastructure, driven by both public funding and private sector participation, positioning the country as a key innovation hub within the Asia Pacific multiomics landscape..
Key Market Statistics
- CAGR (2026-2031) 12.7% CAGR
- Market Size, 2026 ~USD 85.4 Million
- Forecast, 2031 ~USD 155.5 Million
- Country South Korea
South Korea Multiomics Market Overview
Market Valuation Growth :
South Korea's multiomics market is valued at $85.4 million in 2026 and is projected to reach $155.5 million by 2031, demonstrating robust expansion driven by increasing adoption of precision medicine and genomic research initiatives.
Superior CAGR Performance :
South Korea's multiomics market grows at 12.7% CAGR, outperforming the global average of 12.3%, reflecting the country's advanced healthcare infrastructure and significant government investment in biotechnology and personalized medicine.
Healthcare Innovation Hub :
South Korea's strong emphasis on precision medicine, coupled with world-class research institutions and biotech companies, positions the nation as a leading multiomics innovation center in Asia Pacific, attracting both domestic and international investments.
Regulatory Support & Infrastructure :
South Korea's progressive regulatory framework and well-established healthcare system provide favorable conditions for multiomics technology adoption, clinical implementation, and commercialization of advanced diagnostic and therapeutic solutions.
South Korea Multiomics Market Dynamics
- The country's advanced biotechnology sector and skilled workforce create a competitive advantage for multiomics technology development and deployment.
- Major pharmaceutical companies and research institutions are actively investing in multiomics platforms to enhance drug discovery and personalized treatment strategies. Looking ahead, South Korea is expected to maintain its position as a regional leader in multiomics adoption through 2031.
- Integration of artificial intelligence with multiomics data analysis, expansion of clinical applications, and growing patient awareness of personalized medicine will drive sustained market expansion.
- Strategic partnerships between domestic biotech firms and global players will further accelerate innovation and market penetration across diagnostic and therapeutic segments..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- South Korea's multiomics market is valued at $85.4 million in 2026 and is forecast to reach $155.5 million by 2031, representing an 82% increase over the five-year period.
- South Korea's 12.7% CAGR exceeds the global average of 12.3%, indicating stronger regional momentum and market maturity in precision medicine adoption.
- South Korea's advanced healthcare infrastructure and government-backed genomic research initiatives are primary catalysts for multiomics market expansion through 2031.
- South Korea is emerging as a key Asia Pacific innovation hub, with increasing investments from both public institutions and private biotechnology firms driving multiomics platform development and clinical implementation.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
South Korea Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biotech & Pharmaceutical Companies : Companies developing multiomics platforms, diagnostics, or therapeutics need South Korea-specific market intelligence to guide R&D investments, clinical trial planning, and market entry strategies in this precision medicine-focused economy.
- Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in South Korea's biotech sector require detailed market sizing, growth projections, and competitive analysis to identify promising multiomics companies and fund allocation decisions.
- Hospital & Diagnostic Networks : Healthcare providers and diagnostic laboratories in South Korea need market insights to assess multiomics technology adoption trends, reimbursement potential, and competitive positioning for service expansion and technology integration.
- Government & Policy Makers : South Korean health authorities and policy organizations require market data to inform precision medicine initiatives, healthcare funding decisions, and regulatory frameworks supporting multiomics innovation and clinical implementation.
- Research Institutions & Academia : Universities and research centers in South Korea need market intelligence to align multiomics research programs with commercial opportunities, identify collaboration partners, and secure funding for translational research initiatives.
Reasons to Buy this Report
- Market-Specific Growth Projections : Access detailed forecasts for South Korea's multiomics market from 2026-2031, including segment breakdowns, enabling precise investment planning and resource allocation tailored to this high-growth regional market.
- Competitive Landscape Analysis : Understand South Korea's unique competitive dynamics, key players, market consolidation trends, and strategic positioning of domestic biotech firms versus international competitors operating in the Korean multiomics ecosystem.
- Regulatory & Policy Insights : Gain comprehensive understanding of South Korea's healthcare regulations, government incentives for precision medicine, reimbursement policies, and clinical adoption pathways specific to multiomics technologies and applications.
- Investment & Partnership Opportunities : Identify high-potential investment targets, collaboration opportunities with South Korean research institutions, and strategic entry points for companies seeking to expand their multiomics presence in this advanced healthcare market.
- Clinical & Commercial Implementation : Learn about South Korea's healthcare infrastructure readiness, hospital adoption rates, clinical trial landscape, and commercialization strategies specific to multiomics diagnostics and therapeutics in the Korean market.
Frequently asked questions
What is the current size of South Korea's multiomics market?
South Korea's multiomics market is valued at $85.4 million in 2026, with expectations to grow significantly through the forecast period.
What is the projected market size for South Korea's multiomics sector by 2031?
South Korea's multiomics market is projected to reach $155.5 million by 2031, representing substantial growth from the 2026 baseline.
What is South Korea's multiomics market CAGR?
South Korea's multiomics market is expected to grow at a compound annual growth rate of 12.7% between 2026 and 2031.
How does South Korea's multiomics market growth compare to global trends?
South Korea's 12.7% CAGR outpaces the global multiomics market CAGR of 12.3%, reflecting stronger regional adoption and investment momentum.
What factors are driving growth in South Korea's multiomics market?
South Korea's multiomics market growth is driven by advanced healthcare infrastructure, government support for genomic research, increasing precision medicine adoption, and rising investments from biotechnology firms.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- Canada Multiomics Market
- US Multiomics Market
- Germany Multiomics Market
- UK Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- China Multiomics Market
- Japan Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Europe Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
